Big Data and Cloud computing in healthcare and drug development industries have always been one of the major research themes I wanted to learn more about. In this editorial theme, I am fortunate and lucky enough to be invited to technology (shall be referred as tech in subsequent text) events, and to meet up with representatives of tech firms who are making a difference in the healthcare industries, education and, engineering and scientific research work.
I hope you will learn more about the ongoing interesting work in tech firms, and on how programming or coding relates to a better healthcare and drug development. You will also be learning the profile of a technopreneur, Sir Tom Blundell.
Due to some of my long-standing questions on Cancer, I also took the opportunity to interview a renowned scientist, Prof Zhimin Lu.
To give APBN readers a better overview of the healthcare industry, it is important to not neglect the focus on insurance companies, and in this issue AXA Assistance will be sharing with you their views on Regenerative Medicine.
- Yuhui N. Lin